S. Ojoo

Recent transmission of tuberculosis in a cohort of HIV‐1‐infected female sex workers in Nairobi, Kenya

F. Plummer, D. Warrell, J. Ojoo, 1997, AIDS.

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.

P. Kaleebu, A. Siika, B. Castelnuovo, 2022, The lancet. HIV.

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

P. Easterbrook, H. Namata, A. Siika, 2018, The Lancet. Infectious diseases.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

P. Easterbrook, T. Peto, N. French, 2017, The lancet. HIV.

Decreased HIV-associated mortality rates during scale-up of antiretroviral therapy, 2011-2016: a population-based cohort study.

K. D. de Cock, M. Sewe, M. Borgdorff, 2019, AIDS.

Factors Associated with Loss to Follow-up among Patients Receiving HIV Treatment in Nairobi, Kenya.

M. Lavoie, D. Riedel, A. Katana, 2021, AIDS research and human retroviruses.

Treatment Outcomes of Recommended First-Line Antiretroviral Regimens in Resource-Limited Clinics

R. Redfield, M. Hossain, Robert Sheneberger, 2012, Journal of Acquired Immune Deficiency Syndromes.

Decreased HIV-associated mortality rates during scale-up of antiretroviral therapy, 2011-2016.

K. D. de Cock, M. Sewe, M. Borgdorff, 2019 .

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

P. Easterbrook, N. French, H. Namata, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immune response following oral administration of cholera toxin B subunit to HIV‐1-infected UK and Kenyan subjects

G. Dougan, C. Gilks, G. Griffin, 1994, AIDS.